A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.
Inclusion Criteria:
Exclusion Criteria:
Note: If study KGBI is still blinded at the time of rollover to study KGBJ, conditions deemed related to the study treatment will be considered related to lebrikizumab.
Buenos Aires, Buenos Aires 1012, Argentina
Buenos Aires, Buenos Aires C1426ABP, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires 1425, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires C1425DKG, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires 1027, Argentina
Nantes, Loire-Atlantique 44093 Cedex 1, France
Las, Las Palmas 35010, Spain
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
Taipei, Taipei 10002, Taiwan
Taipei, Taipei 11217, Taiwan